Imugene Stock News

Why is this cancer therapy company impressing investors today? The post Imugene share price (ASX:IMU) pops 5% in cancer trial update appeared first on The Motley Fool Australia .

Imugene Limited (ASX:IMU, OTC:IUGNF) continues to make headway on its first-in-human dose-escalation study using the CHECKvacc drug candidate against metastatic, triple-negative breast cancer (TNBC).

The biopharma company share price is in the red. The post Inclusion: Why is the Imugene (ASX:IMU) share price falling today? appeared first on The Motley Fool Australia .

Imugene Limited (ASX:IMU, OTC:IUGNF) and Archer Materials Ltd (ASX:AXE, OTC:ARRXF) are beneficiaries of the S&P Dow Jones Indices December 2021 quarterly rebalance of the S&P/ASX Indices. Clinical-sta

Shares in the biopharma company are enjoying a good run this year. We take a closer look The post The Imugene (ASX:IMU) share price has rocketed 80% since August. Heres why appeared first on The Motley Fool Australia .

Paul Hopper, the man behind Viralytics, Imugene (ASX:IMU) and Chimeric Therapeutics (ASX:CHM), is about to launch another biotech venture Read More The post Paul Hopper on whether his new venture Radiopharm Theranostics will be a takeover target, and the keys to biotech success appeared first on Stockhead .

Sydney, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:

Imugene Limited (ASX:IMU, OTC:IUGNF) is buoyed by a new research report from Roth Capital Partners after signing a clinical trial supply agreement with Merck KGaA and Pfizer to assess IMU's pept

(RTTNews) - Imugene (IMU.AX) said Wednesday that it has reached a new clinical trial supply agreement with Merck KgaA (MKGAY.PK) and Pfizer Inc. (PFE) to evaluate the safety and efficacy of Imugene''s HER-Vaxx in combination with avelumab, an immune checkpoint inhibitor targeting PD-L1, in patients with HER-2 positive gastric cancer.

New clinical trial supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. Avelumab (BAVENCIO ® ) to be provided to Imugene for Phase 2 clinical study in HER-2 positive gastric or gastroesophageal junction adenocarcinomas (neoHERIZON) neoHERIZON will assess HER-Vaxx in combination with chemotherapy with or without avelumab in HER-2 positive gastric cancer SYDNEY, Australia., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Imugene (ASX: IMU) today announced a new clinical trial supply agreement with Merck KGaA, Darmstadt, Germany (ETR: MRK) and Pfizer Inc. (NYSE: PFE ) to evaluate the safety and efficacy of Imugene''s HER-Vaxx, a B-cell activating immunotherapy, in combination with avelumab, an immune checkpoint inhibitor targeting PD-L1, in patients with HER-2 positive gastric cancer. Avelumab, which is marketed as BAVENCIO ® , is co-developed and co-commercialized by Merck KGaA, Darmstadt, Germany and Pfizer Inc. neoHERIZON is an open-label, multi-center, randomized, Phase 2 clinical trial designed to assess the safety and efficacy of perioperative HER-Vaxx combined with chemotherapy with or without avelumab compared to chemotherapy alone in patients with HER-2 positive gastric or gastroesophageal junction adenocarcinomas.

These ASX shares are on form today The post Why Calix, Imugene, Legacy Iron Ore, and Lovisa shares are charging higher appeared first on The Motley Fool Australia .

The ASX 200 Health Index (XHJ) is down by 0.30% at the time of writing, compared to the broader index Read More The post ASX Health Stocks: Imugene joins forces with Merck and Pfizer for Phase 2 trial on gastric cancer appeared first on Stockhead .

Cooperation between drug developers could speed up the delivery of effective treatments. The post Imugene (ASX:IMU) share price leaps 9% on Pfizer, Merck deal appeared first on The Motley Fool Australia .

Imugene Limited (ASX:IMU, OTC:IUGNF) has advanced another treatment in its development pipeline through a clinical trial supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc (NYSE:P

Imugene Limited (ASX:IMU, OTC:IUGNF), a clinical-stage immuno-oncology company developing a range of novel immunotherapies, has received a Buy rating from Roth Capital Partners as well as an updated s